Biocryst Pharmaceuticals (BCRX) Accumulated Expenses: 2010-2015
Historic Accumulated Expenses for Biocryst Pharmaceuticals (BCRX) over the last 3 years, with Sep 2015 value amounting to $23.0 million.
- Biocryst Pharmaceuticals' Accumulated Expenses rose 104.65% to $23.0 million in Q3 2015 from the same period last year, while for Sep 2015 it was $23.0 million, marking a year-over-year increase of 104.65%. This contributed to the annual value of $6.0 million for FY2014, which is 5.00% up from last year.
- According to the latest figures from Q3 2015, Biocryst Pharmaceuticals' Accumulated Expenses is $23.0 million, which was up 21.19% from $19.0 million recorded in Q2 2015.
- Biocryst Pharmaceuticals' Accumulated Expenses' 5-year high stood at $23.0 million during Q3 2015, with a 5-year trough of $5.7 million in Q4 2013.
- In the last 3 years, Biocryst Pharmaceuticals' Accumulated Expenses had a median value of $7.7 million in 2013 and averaged $11.0 million.
- Its Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 41.76% in 2013, then surged by 159.97% in 2015.
- Quarterly analysis of 5 years shows Biocryst Pharmaceuticals' Accumulated Expenses stood at $12.6 million in 2011, then fell by 21.85% to $9.9 million in 2012, then slumped by 41.76% to $5.7 million in 2013, then grew by 5.00% to $6.0 million in 2014, then soared by 104.65% to $23.0 million in 2015.
- Its last three reported values are $23.0 million in Q3 2015, $19.0 million for Q2 2015, and $12.3 million during Q1 2015.